Accelerating antibody discovery with cell-free DNA synthesis
Developing antibody therapeutics requires multiple arduous steps, including synthesizing lead candidate genes, cloning them into vectors, and amplifying plasmids in Escherichia coli cells. Recent strides in synthetic biology and automation have enabled the efficient in vitro generation of synthetic DNA products. In this webinar brought to you by Telesis Bio, Jasmine Hershewe will discuss a cell-free approach to automating DNA printing, cloning, and amplification, expediting the screening and identification of lead antibody candidates.
Topics to be covered:
- Generating DNA constructs for small-scale antibody expression and screening
- Transitioning from digital sequences to transfection ready DNA within a week
Jasmine Hershewe, PhD
Field Application Scientist, Manager
Dr. Hershewe currently leads the global field applications science group at Telesis Bio. Before joining the commercial organization, she developed products on the BioXp system, beginning with biochemistry formulations on the bench, then translating the workflows to the automation platform. She received her PhD from Northwestern University, where doctoral her work focused on engineering platforms for on-demand protein production and in vitro biology.